Capricor's Duchenne muscular dystrophy cell therapy receives three-month FDA review extension

The FDA extends its review of Capricor Therapeutics' experimental Duchenne muscular dystrophy cell therapy, deramiocel, by three months to November 22, 2026. The delay follows Capricor's submission of 24-month data to support a refined indication focused on upper limb function, pivoting from a previously rejected cardiomyopathy indication. While an advisory panel raised efficacy concerns, Capricor reports statistically significant benefits in its clinical trial.

FDA review extension

• ▪The U.S. Food and Drug Administration extended the review period for Capricor Therapeutics' experimental cell therapy, deramiocel, by three months to November 22, 2026.
• ▪Capricor Therapeutics' shares rose 15% to $7.25 on August 24, 2026, after the company announced the U.S. Food and Drug Administration's review extension.
• ▪The U.S. Food and Drug Administration classified Capricor Therapeutics' new data submission as a "major amendment," triggering the three-month review extension.

Upper limb function indication

• ▪Capricor Therapeutics Chief Executive Officer Linda Marban stated that the company's additional follow-up data provides one of the most extensive clinical datasets evaluating upper limb function in Duchenne muscular dystrophy.
• ▪Capricor Therapeutics submitted an amendment to its application with a refined proposed indication for deramiocel focused on improving upper limb muscle function.
• ▪H.C. Wainwright analysts stated that the key question remains whether Capricor Therapeutics' new data and analyses can address the U.S. Food and Drug Administration's concerns to support approval for the refined upper limb function indication.

Advisory panel efficacy concerns

• ▪An FDA advisory panel voted against the effectiveness data of Capricor Therapeutics' deramiocel for treating cardiomyopathy in Duchenne muscular dystrophy patients.
• ▪U.S. Food and Drug Administration staff flagged concerns regarding changes made by Capricor Therapeutics to how the company measured its clinical trial results.
• ▪The U.S. Food and Drug Administration previously rejected approval for deramiocel to treat cardiomyopathy because the treatment did not meet efficacy requirements.

Deramiocel clinical trial data

• ▪Capricor Therapeutics Chief Executive Officer Linda Marban stated that the late-stage clinical trial for deramiocel met its primary goal with a statistically significant benefit.
• ▪Capricor Therapeutics' new submission to the U.S. Food and Drug Administration includes 24-month follow-up data and extra analyses from its late-stage study of deramiocel.

Duchenne muscular dystrophy treatment

• ▪Duchenne muscular dystrophy is a rare genetic disease that affects approximately 15,000 people in the United States, primarily boys.
• ▪The U.S. Food and Drug Administration accepted Capricor Therapeutics' amended application citing a high unmet medical need for patients with Duchenne muscular dystrophy.

2 sources